Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...
pharmaphorum16m
Changing Faces: Pharma and biotech hires – February 2025
February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Hims & Hers Stock (HIMS) Soars on Plans to Shutter Acne Treatment Unit
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...
How to eat well with diabetes – and save money doing it
How to eat well with diabetes – and save money doing it - Miguel Barclay has built a reputation on proving that good food ...
South African Competition Commission probes Novo Nordisk and Sanofi over insulin pen market
South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over their insulin pen market practices, amid growing concerns about ...
Shocking stories of people who went blind after taking Ozempic and Mounjaro
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...